Evidence map›Paper›PMID 39894750›Full record

ArticleBritish journal of anaesthesia2025

Evaluation of the need for dosing adaptations in obese patients for surgical antibiotic prophylaxis: a model-based analysis of cefazolin pharmacokinetics.

Davide Bindellini, Philipp Simon, David Busse, Robin Michelet, David Petroff, Linda B S Aulin, Christoph Dorn, Markus Zeitlinger, Wilhelm Huisinga, Hermann Wrigge and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of anaesthesia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Davide BindelliniDepartment of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, Germany; Graduate Research Training Programme, PharMetrX, Berlin, Germany.
Philipp SimonDepartment of Anaesthesiology and Operative Intensive Care, Faculty of Medicine, University of Augsburg, Augsburg, Germany; Integrated Research and Treatment Center (IFB), Adiposity Diseases, University of Leipzig, Leipzig, Germany; Department of Anesthesiology and Intensive Care Medicine, University of Leipzig Medical Center, Leipzig, Germany. Electronic address: Philipp.Simon3@uk-augsburg.de.
David BusseDepartment of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, Germany; Graduate Research Training Programme, PharMetrX, Berlin, Germany; Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany.
Robin MicheletDepartment of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, Germany.
David PetroffClinical Trial Centre Leipzig, University of Leipzig, Leipzig, Germany.
Linda B S AulinDepartment of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, Germany.
Christoph DornInstitute of Pharmacy, University of Regensburg, Regensburg, Germany.
Markus ZeitlingerDepartment of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
Wilhelm HuisingaInstitute of Mathematics, University of Potsdam, Potsdam, Germany.
Hermann WriggeIntegrated Research and Treatment Center (IFB), Adiposity Diseases, University of Leipzig, Leipzig, Germany; Bergmannstrost Hospital Halle, Department of Anaesthesiology, Intensive Care and Emergency Medicine, Pain Therapy, Halle, Germany; Medical Faculty, Martin-Luther-University Halle-Wittenberg, Halle, Germany.
Charlotte KloftDepartment of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, Germany. Electronic address: charlotte.kloft@fu-berlin.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCefazolin is used as a prophylactic antibiotic to reduce surgical site infections (SSIs). Obesity has been identified as a risk factor for SSIs. Cefazolin dosing recommendations and guidelines are currently inconsistent for obese patients. As plasma and target-site exposure might differ, pharmacokinetic data from the sites of SSIs are essential to evaluate treatment efficacy: these data can be obtained via tissue microdialysis. This analysis was designed to evaluate the need for dosing adaptations in obese patients for surgical prophylaxis.

methodsData from 15 obese (BMI

resultsEvaluation of cefazolin doses of 1 and 2 g with redosing at either 3 or 4 h by PTA and CFR in plasma and ISF found 2 g cefazolin with redosing at 4 h to be the most suitable dosing regimen for both obese and nonobese patients (PTA >90% and CFR >90% for both).

conclusionsThis model-based analysis, using fT

Indexed as

Anti-Bacterial AgentsAntibiotic ProphylaxisCefazolinObesitySurgical Wound InfectionAdultAgedDose-Response Relationship, DrugFemaleHumansMaleMiddle AgedModels, BiologicalAnti-Bacterial AgentsCefazolincefazolinmicrodialysisobesitypharmacokineticspopulation analysissurgical antibiotic prophylaxis

Identifiers

PMID39894750
PMCPMC11947583

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.